Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Savitz Ryan sold 31,249 Dianthus Therapeutics, Inc. shares (Form 4)
Traded Jul 9, 2026 · Filed Jul 13, 2026
On Jul 9, 2026, Savitz Ryan (EVP, CFO & CBO) sold 31,249 Dianthus Therapeutics, Inc. shares at an average US$101.03 for US$3.16M under a trading plan, leaving 0 shares. Filed Jul 13, 2026 (Form 4).
- Sold
- 31,249 shares
- Price
- US$101.03 average (US$100.22 to US$101.97)
- Value
- US$3.16M
- Holding after
- 0 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- EVP, CFO & CBO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Common Stock | Option exercise | 31,249 | US$21.77 | 31,249 | Direct |
| Jul 9, 2026 | Common Stock | Sale | 10,354 | US$100.22 | 20,895 | Direct |
| Jul 9, 2026 | Common Stock | Sale | 15,329 | US$101.24 | 5,566 | Direct |
| Jul 9, 2026 | Common Stock | Sale | 5,566 | US$101.97 | 0 | Direct |
Source
Related
- Dianthus Therapeutics, Inc.
- Savitz Ryan
- Dianthus Therapeutics, Inc. shareholders
- Form 4 · Savitz Ryan · Apr 10, 2026
- Form 4 · Savitz Ryan · Apr 1, 2026
- Form 4 · Carr Edward · Sep 18, 2026
- Form 4 · Randhawa Simrat · Sep 3, 2026
- Form 4 · Read Simon · Aug 19, 2026
- Form 4 · Veness Adam M · Aug 14, 2026
- Schedule 13G/A · Sirenia Capital Management LP · Aug 14, 2026